US20020177617A1 - Method of treating migraines and pharmaceutical compositions - Google Patents

Method of treating migraines and pharmaceutical compositions Download PDF

Info

Publication number
US20020177617A1
US20020177617A1 US10/106,845 US10684502A US2002177617A1 US 20020177617 A1 US20020177617 A1 US 20020177617A1 US 10684502 A US10684502 A US 10684502A US 2002177617 A1 US2002177617 A1 US 2002177617A1
Authority
US
United States
Prior art keywords
cox
agonist
rizatriptan
vioxx
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/106,845
Inventor
Kremena Simitchieva
Scott Reines
Errol McKinney
Eric Sandquist
Deepak Khannna
Richard Hargreaves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US10/106,845 priority Critical patent/US20020177617A1/en
Publication of US20020177617A1 publication Critical patent/US20020177617A1/en
Priority to US11/372,694 priority patent/US20060194855A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Definitions

  • Migraines are recurrent, often familial, symptom complexes of periodic attacks of vascular headache. Migraines affect approximately 17% of adult women and 6% of adult men (Stewart et al., Neurology, 1994, 44 (suppl. 4), 517-523).
  • Activation of 5-HT 1B and/or 5-HT 1D receptors leads to (1) selective vasoconstriction of certain cranial extracerebral blood vessel segments; (2) pre-junctional inhibition of the release of proinflammatory neuropeptides from sensory nerve terminals in the meninges; and (3) attenuation of central nociceptive neurotransmission by inhibition of neurotransmitter release within the trigeminal nucleus caudalis. It is believed that one or more of these three mechanisms is involved in the anti-migraine action of 5-HT 1B/1D receptor agonists such as rizatriptan.
  • Cyclooxygenase also known as prostaglandin H synthase, is an enzyme implicated in the mediation of pain, fever and inflammation. It catalyzes the oxidative conversion of arachidonic acid into prostaglandin H 2 , a key intermediate in the biosynthetic pathway of prostaglandins, prostacyclins and thromboxanes, which in turn mediate a variety of physiological effects both beneficial and pathological.
  • COX-1 expressed constitutively in many tissues
  • COX-2 an induced isoform having elevated levels of expression in inflamed tissues.
  • COX-1 is thought to be involved in ongoing “housekeeping” functions, for example, gastric cytoprotection, while COX-2 is implicated in the pathological effects mentioned above.
  • COX-2 selective inhibitors act as effective NSAIDs without substantial gastrotoxic side effects.
  • a COX-2 selective inhibitor is defined as a COX inhibitor having a selectivity for the COX-2 isoform relative to the COX-1 isoform.
  • migraines can be more effectively treated and/or controlled by the co-administration of a 5-HT 1B/1D receptor agonist in combination with a COX-2 selective inhibitor, than with a 5HT 1B/1D agonist alone, and more safely than with a traditional analgesic in combination with a 5HT agonist.
  • the present invention relates to a method of treating or preventing migraines in a mammalian patient in need thereof, which comprises administering to said patient an anti-migraine effective amount of a combination of a COX-2 selective inhibitor and a 5-HT 1B/1D receptor agonist.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a COX-2 selective inhibitor, a 5-HT 1B/1D receptor agonist and a pharmaceutically acceptable carrier therefore.
  • One embodiment of the present invention is a method of treating or preventing migraine with an anti-migraine effective amount of a combination of a 5HT 1B/1D agonist and a COX-2 selective inhibitor.
  • Another embodiment of the invention is a pharmaceutical composition comprising a combination of a 5HT 1B/1D agonist and a COX-2 selective inhibitor and a pharmaceutically acceptable carrier.
  • examples of the 5HT 1B/1D agonist can be selected from rizatriptan (EP 0,497,512), sumatriptan (GB 2,162,522), naratriptan (GB 2,208,646), zolmitriptan (WO91/18897), eleptriptan (WO92/06973), and almotriptan (WO94/02460).
  • the preferred 5HT 1B/1D agonist for use in this invention is rizatriptan, which is N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, the benzoate salt thereof being particularly preferred.
  • COX-2 inhibitors useful in the methods and compositions described herein include Celebrex® (celecoxib), VIOXX®, MK-663 (WO98/03484), compounds disclosed in WO07/14691, meloxicam, RS 57067, valdecoxib (U.S. Pat. No. 5,663,272) and a compound of the structure:
  • the two active ingredients can be administered combined in a single dosage form such as described as one embodiment of this invention, or as two separate dosage forms, each containing one of the active ingredients, the two being administered substantially concurrently.
  • a method of treating or preventing migraine is disclosed in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective inhibiting compound and a 5HT 1B/1D agonist, or salts or hydrates thereof, in amounts that are effective for treating or preventing migraines.
  • the 5HT 1B/1D agonist is selected from the group consisting of: sumitriptan, naratriptan, zolmitriptan, eleptriptan, almatriptan and rizatriptan and the COX-2 selective inhibiting compound is selected from the group consisting of: meloxicam, 2-(6-methylpyrid-3-yl)-3-(4-methylsulfonylphenyl)-5-chloropyridine (MK-663), VIOXX® (valdecoxib), RS 57067, Celebrex® (celecoxib), and a compound of structure:
  • COX-2 selective inhibitor is VIOXX® and the 5HT 1B/1D agonist is rizatriptan or a salt or hydrate thereof.
  • the method is described wherein the 5HT 1B/1D agonist and COX-2 inhibitor are administered combined in a single dosage form.
  • the method is described wherein the 5HT 1B/1D agonist and COX-2 inhibitor are administered as separate dosage forms substantially concurrently.
  • a pharmaceutical composition is included herein which is comprised of a 5HT 1B/1D agonist and a COX-2 selective inhibiting compound, or salts or hydrates thereof, in combination with a pharmaceutically acceptable carrier.
  • the composition is described wherein the 5HT 1B/1D agonist is selected from sumitriptan, naratriptan, zolmitriptan, eleptriptan, almatriptan and rizatriptan, and the COX-2 inhibitor is selected from MK-663, VIOXX®, meloxicam, RS57067, celoxib, valdecoxib and a compound of structure:
  • composition wherein the 5HT 1B/1D agonist is rizatriptan or a salt thereof, and the COX-2 inhibitor is VIOXX®.
  • a composition wherein rizatriptan or a salt thereof, is present in an amount ranging from about 1 to about 10 mg, and VIOXX® is present in an amount ranging from about 10 mg to about 100 mg. More particularly, the rizatriptan is present as the benzoate salt, and VIOXX.
  • An anti-migraine effective amount of the combination is that amount that will relieve the subject being treated of the symptoms of the migraine attack and the specific dose level and frequency of dosage may vary and will depend upon a variety of factors including the activity of the specific compounds used in combination, the metabolic stability and length of action of the compounds, the age, body weight, general health, sex diet, mode and time of administration, rate of excretion, the severity of the particular condition and the host undergoing therapy.
  • dosage levels of the 5HT 1B/1D on the order of about 0.001 mg/kg to about 250 mg/kg of body weight per day, typically about 0.005 to about 100 mg/kg, more particularly about 0.01 to about 50 mg/kg and especially about 0.05 to about 10 mg/kg per day are useful in the novel method of treatment.
  • Dosage levels of the COX-2 inhibitor of about 0.1 to 500 mg/kg of body weight per day, typically about 0.5 to about 250 mg/kg, more particularly about 5 to about 100 mg/kg and especially about 10 to about 50 mg/kg of body weight per day are useful in the novel method of this invention.
  • the active ingredients may be administered orally, topically, parenterally, by inhalation, spray, rectally or intravaginally in formulations containing pharmaceutically acceptable carriers.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasisternal injection or infusion techniques.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and typically such compositions contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preservatives in order to provide pharmaceutically elegant and palatable preparations.
  • excipients may be for example, diluents such as lactose, calcium carbonate, sodium carbonate, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • diluents such as lactose, calcium carbonate, sodium carbonate, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents for example, corn starch or alginic acid
  • binding agents for example starch, gelatin or acacia
  • lubricating agents for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated. Coating can be included to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or miscible solvents such as propylene glycol, PEGs and ethanol
  • an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, tragacanth and acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • preservatives for example ethyl or n-propyl p-hydroxybenzoate
  • colouring agents for example ethyl or n-propyl p-hydroxybenzoate
  • flavouring agents such as sucrose, saccharin or aspartame.
  • sweetening agents such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent exemplified by those already mentioned above.
  • Additional excipients for example sweetening, flavouring and colouring agents, may also be present.
  • the individual agents or the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxy-ethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain demulcents, preservatives, flavourants and colouring agents.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain demulcents, preservatives, flavourants and colouring agents.
  • compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • Injectable compositions are typically in the form of sterile solutions or suspensions, which include the active ingredient in a parenterally-acceptable diluent.
  • sterile water dextrose 5% in water (D5W)
  • Ringer's solution and isotonic saline, as well as mixtures thereof.
  • Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used.
  • Sterile, injectable oil is occasionally employed as a solvent or suspending medium in intramuscular preparations.
  • a representative example is peanut oil.
  • fatty acids such as oleic acid, preservatives, buffers and local anesthetics find use in the preparation of intramuscular injectables.
  • the combination of active ingredients may also be administered rectally or intravaginally as suppositories.
  • suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary room temperature but molten at normal or elevated body temperature. Examples of such materials include cocoa butter and polyethylene glycols.
  • Topical formulations are comprised of a pharmaceutical carrier, which may include, e.g., cosolvents, emulsifiers, penetration enhancers, preservatives or emollients.
  • a formulation intended for oral administration may contain from as low as about 0.1 mg of the novel combination to as high as about 5 g of combination per dose, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Tablets containing 5 mg and 10 mg of rizatriptan benzoate and 10 mg of Vioxx were prepared as follows: Example 1 Example 2 Rizatriptan benzoate 5.0 mg 10.0 mg Vioxx 10.0 mg 10.0 mg Microcrystalline cellulose 42.0 mg 39.5 mg Modified food corn starch 42.0 mg 39.5 mg Magnesium stearate 1.0 mg 1.0 mg

Abstract

A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

Description

    BACKGROUND OF THE INVENTION
  • Migraines are recurrent, often familial, symptom complexes of periodic attacks of vascular headache. Migraines affect approximately 17% of adult women and 6% of adult men (Stewart et al., [0001] Neurology, 1994, 44 (suppl. 4), 517-523).
  • It has been known for some time that sumatriptan, which causes constriction of cranial blood vessels, is an effective treatment for migraine (see, for example, Doenicke et al., [0002] Lancet, 1988, Vol. 1, 1309-11; and Feniuk & Humphrey, Drug Development Research, 1992, 26, 235-40). As such, it is the prototypical example of a class of compounds, including rizatriptan, which have recently been classified (Hartig et al., TIPS, 1996, 17, 103-105) as 5-HT1B/1D receptor agonists.
  • Activation of 5-HT[0003] 1B and/or 5-HT1D receptors leads to (1) selective vasoconstriction of certain cranial extracerebral blood vessel segments; (2) pre-junctional inhibition of the release of proinflammatory neuropeptides from sensory nerve terminals in the meninges; and (3) attenuation of central nociceptive neurotransmission by inhibition of neurotransmitter release within the trigeminal nucleus caudalis. It is believed that one or more of these three mechanisms is involved in the anti-migraine action of 5-HT1B/1D receptor agonists such as rizatriptan.
  • Cyclooxygenase (COX), also known as prostaglandin H synthase, is an enzyme implicated in the mediation of pain, fever and inflammation. It catalyzes the oxidative conversion of arachidonic acid into prostaglandin H[0004] 2, a key intermediate in the biosynthetic pathway of prostaglandins, prostacyclins and thromboxanes, which in turn mediate a variety of physiological effects both beneficial and pathological. Recently it was discovered that two COX isoforms exist: COX-1, expressed constitutively in many tissues, and COX-2, an induced isoform having elevated levels of expression in inflamed tissues. COX-1 is thought to be involved in ongoing “housekeeping” functions, for example, gastric cytoprotection, while COX-2 is implicated in the pathological effects mentioned above.
  • Current cyclooxygenase inhibitors such as aspirin, ibuprofen and indomethacin, used as non-steroidal anti-inflammatory drugs (NSAIDs), inhibit both COX-1 and COX-2 and have associated side effects, such as gastrotoxicity, which may be manifested as ulcer formation. COX-2 selective inhibitors act as effective NSAIDs without substantial gastrotoxic side effects. For purposes of this disclosure only, a COX-2 selective inhibitor is defined as a COX inhibitor having a selectivity for the COX-2 isoform relative to the COX-1 isoform. [0005]
  • The treatment of migraines by coadministration of a 5HT agonist and a traditional analgesic, including a NSAID has been described in international patent application WO98/06392. [0006]
  • It has now been found that migraines can be more effectively treated and/or controlled by the co-administration of a 5-HT[0007] 1B/1D receptor agonist in combination with a COX-2 selective inhibitor, than with a 5HT1B/1D agonist alone, and more safely than with a traditional analgesic in combination with a 5HT agonist.
    • SUMMARY OF THE INVENTION
  • The present invention relates to a method of treating or preventing migraines in a mammalian patient in need thereof, which comprises administering to said patient an anti-migraine effective amount of a combination of a COX-2 selective inhibitor and a 5-HT[0008] 1B/1D receptor agonist.
  • The invention also relates to a pharmaceutical composition comprising a COX-2 selective inhibitor, a 5-HT[0009] 1B/1D receptor agonist and a pharmaceutically acceptable carrier therefore.
    • DETAILED DESCRIPTION
  • One embodiment of the present invention is a method of treating or preventing migraine with an anti-migraine effective amount of a combination of a 5HT[0010] 1B/1D agonist and a COX-2 selective inhibitor. Another embodiment of the invention is a pharmaceutical composition comprising a combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor and a pharmaceutically acceptable carrier.
  • In these two embodiments, examples of the 5HT[0011] 1B/1D agonist can be selected from rizatriptan (EP 0,497,512), sumatriptan (GB 2,162,522), naratriptan (GB 2,208,646), zolmitriptan (WO91/18897), eleptriptan (WO92/06973), and almotriptan (WO94/02460).
  • The preferred 5HT[0012] 1B/1D agonist for use in this invention is rizatriptan, which is N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, the benzoate salt thereof being particularly preferred.
  • Examples of COX-2 inhibitors useful in the methods and compositions described herein include Celebrex® (celecoxib), VIOXX®, MK-663 (WO98/03484), compounds disclosed in WO07/14691, meloxicam, RS 57067, valdecoxib (U.S. Pat. No. 5,663,272) and a compound of the structure: [0013]
    Figure US20020177617A1-20021128-C00001
  • In the novel method of treatment described herein, the two active ingredients can be administered combined in a single dosage form such as described as one embodiment of this invention, or as two separate dosage forms, each containing one of the active ingredients, the two being administered substantially concurrently. [0014]
  • In one aspect of the invention, a method of treating or preventing migraine is disclosed in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective inhibiting compound and a 5HT[0015] 1B/1D agonist, or salts or hydrates thereof, in amounts that are effective for treating or preventing migraines.
  • More particularly, a method is disclosed wherein the 5HT[0016] 1B/1D agonist is selected from the group consisting of: sumitriptan, naratriptan, zolmitriptan, eleptriptan, almatriptan and rizatriptan and the COX-2 selective inhibiting compound is selected from the group consisting of: meloxicam, 2-(6-methylpyrid-3-yl)-3-(4-methylsulfonylphenyl)-5-chloropyridine (MK-663), VIOXX® (valdecoxib), RS 57067, Celebrex® (celecoxib), and a compound of structure:
    Figure US20020177617A1-20021128-C00002
  • Even more particularly, a methodis disclosed wherein the COX-2 selective inhibitor is VIOXX® and the 5HT[0017] 1B/1D agonist is rizatriptan or a salt or hydrate thereof.
  • In one aspect, the method is described wherein the 5HT[0018] 1B/1D agonist and COX-2 inhibitor are administered combined in a single dosage form.
  • In another aspect, the method is described wherein the 5HT[0019] 1B/1D agonist and COX-2 inhibitor are administered as separate dosage forms substantially concurrently.
  • In a different aspect, a pharmaceutical composition is included herein which is comprised of a 5HT[0020] 1B/1D agonist and a COX-2 selective inhibiting compound, or salts or hydrates thereof, in combination with a pharmaceutically acceptable carrier.
  • More particularly, the composition is described wherein the 5HT[0021] 1B/1D agonist is selected from sumitriptan, naratriptan, zolmitriptan, eleptriptan, almatriptan and rizatriptan, and the COX-2 inhibitor is selected from MK-663, VIOXX®, meloxicam, RS57067, celoxib, valdecoxib and a compound of structure:
    Figure US20020177617A1-20021128-C00003
  • Even more particularly, the composition is described wherein the 5HT[0022] 1B/1D agonist is rizatriptan or a salt thereof, and the COX-2 inhibitor is VIOXX®.
  • In a preferred combination, a composition is described wherein rizatriptan or a salt thereof, is present in an amount ranging from about 1 to about 10 mg, and VIOXX® is present in an amount ranging from about 10 mg to about 100 mg. More particularly, the rizatriptan is present as the benzoate salt, and VIOXX. [0023]
  • An anti-migraine effective amount of the combination is that amount that will relieve the subject being treated of the symptoms of the migraine attack and the specific dose level and frequency of dosage may vary and will depend upon a variety of factors including the activity of the specific compounds used in combination, the metabolic stability and length of action of the compounds, the age, body weight, general health, sex diet, mode and time of administration, rate of excretion, the severity of the particular condition and the host undergoing therapy. However, dosage levels of the 5HT[0024] 1B/1D on the order of about 0.001 mg/kg to about 250 mg/kg of body weight per day, typically about 0.005 to about 100 mg/kg, more particularly about 0.01 to about 50 mg/kg and especially about 0.05 to about 10 mg/kg per day are useful in the novel method of treatment. Dosage levels of the COX-2 inhibitor of about 0.1 to 500 mg/kg of body weight per day, typically about 0.5 to about 250 mg/kg, more particularly about 5 to about 100 mg/kg and especially about 10 to about 50 mg/kg of body weight per day are useful in the novel method of this invention.
  • For the treatment of a migraine attack, the active ingredients, separately or in combination, may be administered orally, topically, parenterally, by inhalation, spray, rectally or intravaginally in formulations containing pharmaceutically acceptable carriers. [0025]
  • The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasisternal injection or infusion techniques. [0026]
  • The separate active agents or the novel composition of this invention may be in a form suitable for oral use, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, solutions, syrups and elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and typically such compositions contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preservatives in order to provide pharmaceutically elegant and palatable preparations. These excipients may be for example, diluents such as lactose, calcium carbonate, sodium carbonate, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. [0027]
  • The tablets may be uncoated or they may be coated. Coating can be included to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release. [0028]
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin or olive oil. [0029]
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, tragacanth and acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame. [0030]
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. [0031]
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present. [0032]
  • The individual agents or the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxy-ethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents. [0033]
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain demulcents, preservatives, flavourants and colouring agents. [0034]
  • The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. [0035]
  • Injectable compositions are typically in the form of sterile solutions or suspensions, which include the active ingredient in a parenterally-acceptable diluent. Among these are sterile water, dextrose 5% in water (D5W), Ringer's solution and isotonic saline, as well as mixtures thereof. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. Sterile, injectable oil is occasionally employed as a solvent or suspending medium in intramuscular preparations. A representative example is peanut oil. In addition, fatty acids such as oleic acid, preservatives, buffers and local anesthetics find use in the preparation of intramuscular injectables. [0036]
  • The combination of active ingredients may also be administered rectally or intravaginally as suppositories. These can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary room temperature but molten at normal or elevated body temperature. Examples of such materials include cocoa butter and polyethylene glycols. [0037]
  • For topical use, creams, ointments, gels, solutions, suspensions and the like containing the compound are employed. (For purposes of this application, topical application includes mouth washes and gargles, as well as transdermal applications.) Topical formulations are comprised of a pharmaceutical carrier, which may include, e.g., cosolvents, emulsifiers, penetration enhancers, preservatives or emollients. [0038]
  • The active ingredients are combined with the carrier to produce the dosage form. For example, a formulation intended for oral administration may contain from as low as about 0.1 mg of the novel combination to as high as about 5 g of combination per dose, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.[0039]
    • EXAMPLES 1 AND 2
  • Tablet Preparation [0040]
  • Tablets containing 5 mg and 10 mg of rizatriptan benzoate and 10 mg of Vioxx were prepared as follows: [0041]
    Example 1 Example 2
    Rizatriptan benzoate  5.0 mg 10.0 mg
    Vioxx 10.0 mg 10.0 mg
    Microcrystalline cellulose 42.0 mg 39.5 mg
    Modified food corn starch 42.0 mg 39.5 mg
    Magnesium stearate  1.0 mg  1.0 mg
  • All of the active ingredients, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and magnesium stearate. The resulting granulation is then compressed into tablets. [0042]

Claims (10)

What is claimed is:
1. A method of treating or preventing migraine in a mammalian patient in need of such treatment, which comprises administering to the patient a COX-2 selective inhibiting compound and a 5HT1B/1D agonist, or salts or hydrates thereof, in amounts that are effective for treating or preventing migraines.
2. The method according to claim 1 wherein the 5HT1B/1D agonist is selected from the group consisting of: sumitriptan, naratriptan, zolmitriptan, eleptriptan, almatriptan and rizatriptan and the COX-2 selective inhibiting compound is selected from the group consisting of: meloxicam, MK-663, VIOXX®, RS 57067, celecoxib, valdecoxib and a compound of structure:
Figure US20020177617A1-20021128-C00004
3. The method according to claim 2 wherein the COX-2 selective inhibitor is VIOXX® and the 5HT1B/1D agonist is rizatriptan.
4. The method of claim 1 wherein the 5HT1B/1D agonist and COX-2 inhibitor are administered combined in a single dosage form.
5. The method of claim 1 wherein the 5HT1B/1D agonist and COX-2 inhibitor are administered as separate dosage forms substantially concurrently.
6. A pharmaceutical composition which is comprised of a 5HT1B/1D agonist and a COX-2 selective inhibiting compound, or salts or hydrates thereof, in combination with a pharmaceutically acceptable carrier.
7. The composition of claim 6 wherein the 5HT1B/1D agonist is selected from sumitriptan, naratriptan, zolmitriptan, eleptriptan, almatriptan and rizatriptan, and the COX-2 inhibitor is selected from MK-663, VIOXX®, meloxicam, RS57067, celoxib, valdecoxib and a compound of structure:
Figure US20020177617A1-20021128-C00005
8. The composition of claim 7 wherein the 5HT1B/1D agonist is rizatriptan or a salt thereof, and the COX-2 inhibitor is VIOXX®.
9. A composition in accordance with claim 7 wherein rizatriptan or a salt thereof, is present in an amount ranging from about 1 to about 10 mg, and VIOXX® is present in an amount ranging from about 10 mg to about 100 mg.
10. A composition in accordance with claim 8 wherein the rizatriptan is present in the form of the benzoate salt.
US10/106,845 1998-11-02 2002-03-26 Method of treating migraines and pharmaceutical compositions Abandoned US20020177617A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/106,845 US20020177617A1 (en) 1998-11-02 2002-03-26 Method of treating migraines and pharmaceutical compositions
US11/372,694 US20060194855A1 (en) 1998-11-02 2006-03-10 Method of treating migraines and pharmaceutical compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10660598P 1998-11-02 1998-11-02
US42927499A 1999-10-29 1999-10-29
US09/934,823 US6384034B2 (en) 1998-11-02 2001-08-22 Method of treating migraines and pharmaceutical compositions
US10/106,845 US20020177617A1 (en) 1998-11-02 2002-03-26 Method of treating migraines and pharmaceutical compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/934,823 Division US6384034B2 (en) 1998-11-02 2001-08-22 Method of treating migraines and pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/372,694 Continuation US20060194855A1 (en) 1998-11-02 2006-03-10 Method of treating migraines and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
US20020177617A1 true US20020177617A1 (en) 2002-11-28

Family

ID=22312313

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/934,823 Expired - Fee Related US6384034B2 (en) 1998-11-02 2001-08-22 Method of treating migraines and pharmaceutical compositions
US10/106,845 Abandoned US20020177617A1 (en) 1998-11-02 2002-03-26 Method of treating migraines and pharmaceutical compositions
US11/372,694 Abandoned US20060194855A1 (en) 1998-11-02 2006-03-10 Method of treating migraines and pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/934,823 Expired - Fee Related US6384034B2 (en) 1998-11-02 2001-08-22 Method of treating migraines and pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/372,694 Abandoned US20060194855A1 (en) 1998-11-02 2006-03-10 Method of treating migraines and pharmaceutical compositions

Country Status (9)

Country Link
US (3) US6384034B2 (en)
EP (1) EP1126841B1 (en)
JP (1) JP2002528498A (en)
AT (1) ATE284691T1 (en)
AU (1) AU759307B2 (en)
CA (1) CA2348979A1 (en)
DE (1) DE69922688T2 (en)
ES (1) ES2234324T3 (en)
WO (1) WO2000025779A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP2002528498A (en) * 1998-11-02 2002-09-03 メルク エンド カムパニー インコーポレーテッド Migraine treatment method and pharmaceutical composition
WO2000048583A2 (en) * 1999-02-19 2000-08-24 Pozen Inc. Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
CO5190664A1 (en) 1999-06-30 2002-08-29 Pfizer Prod Inc COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA ADMINISTRATION OF A 5HT RECEPTOR, CAFFEINE AND A CYCLLOXYGENASA-2 INHIBITOR
DK1150959T3 (en) * 1999-12-08 2008-06-02 Pharmacia Corp Solid state form of Celecoxib which has increased bioavailability
AR035642A1 (en) * 2000-05-26 2004-06-23 Pharmacia Corp USE OF A CELECOXIB COMPOSITION FOR QUICK PAIN RELIEF
AU2001275004A1 (en) * 2000-06-01 2001-12-11 Pharmacia Corporation Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2002096435A2 (en) * 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
DE10129320A1 (en) 2001-06-19 2003-04-10 Norbert Mueller Use of cyclooxygenase-2 inhibitor in the preparation of a medicament for treating psychiatric disorders e.g. schizophrenia
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
KR20040095232A (en) * 2002-02-25 2004-11-12 라이프자트로운 에이치에프 absorption enhancing agent
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
CN100360117C (en) * 2002-06-21 2008-01-09 转化医药公司 Pharmaceutical compositions with improved dissolution
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
PT1575566E (en) * 2002-12-26 2012-03-29 Pozen Inc Multilayer dosage forms containing naproxen and triptans
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
WO2004071508A1 (en) * 2003-02-14 2004-08-26 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
JP2007516266A (en) * 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー Substituted (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl compounds as 5-HT1F agonists
US20070105927A1 (en) * 2005-10-20 2007-05-10 Glenmark Pharmaceuticals Limited Amorphous rizatriptan benzoate
US20080270221A1 (en) * 2006-12-18 2008-10-30 Silvaris Corporation Determining and presenting product market prices
JP2010516679A (en) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド Diagnostic and therapeutic cyclooxygenase-2 binding ligands
PE20091211A1 (en) * 2007-11-30 2009-09-14 Boehringer Ingelheim Int PYRAZOLOPYRIMIDINE DERIVATIVES AS PDE9A MODULATORS
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP2306998A4 (en) * 2008-06-20 2011-06-15 Alphapharm Pty Ltd Pharmaceutical formulation
AU2009269129B2 (en) 2008-06-30 2015-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy
KR20110063447A (en) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Pyrazolopyrimidines and their use for the treatment of cns disorders
UA105657C2 (en) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Enhanced migraine treatments based on anamorelin
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
AR077859A1 (en) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
MX344770B (en) 2010-08-12 2017-01-06 Boehringer Ingelheim Int Gmbh * 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors.
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
EP3265081A4 (en) 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6870867B2 (en) * 2017-01-04 2021-05-12 アクスサム セラピューティクス インコーポレイテッド Pharmaceutical composition containing meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) * 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2018209150A1 (en) * 2017-05-10 2018-11-15 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) * 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) * 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
PE20212157A1 (en) * 2019-02-06 2021-11-09 Axsome Therapeutics Inc PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
WO2023073513A1 (en) * 2021-10-26 2023-05-04 Alembic Pharmaceuticals Limited Pharmaceutical composition containing combination of meloxicam and rizatriptan and process of preparation thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5760068A (en) * 1993-11-30 1998-06-02 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US5942503A (en) * 1995-11-14 1999-08-24 Boehringer Indelheim Kg Use of Epinastine for the treatment of pain
US6054455A (en) * 1998-05-18 2000-04-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US6310099B1 (en) * 1997-08-28 2001-10-30 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
US6384034B2 (en) * 1998-11-02 2002-05-07 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (en) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives, method of producing same, their use and pharmaceutical compositons on their base
CA2097208C (en) * 1992-06-05 2005-02-08 Raymond Baker The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
JP2636819B2 (en) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 Oxazole-based heterocyclic aromatic compounds
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
WO2000048583A2 (en) 1999-02-19 2000-08-24 Pozen Inc. Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
EP1156855A1 (en) * 1999-03-01 2001-11-28 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
IL136025A0 (en) 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
IL136023A0 (en) 1999-05-14 2001-05-20 Pfizer Prod Inc 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
AU3253800A (en) * 1999-05-14 2000-11-16 Pfizer Products Inc. Combination therapy for the treatment of migraine

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5760068A (en) * 1993-11-30 1998-06-02 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5942503A (en) * 1995-11-14 1999-08-24 Boehringer Indelheim Kg Use of Epinastine for the treatment of pain
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US6479551B1 (en) * 1996-11-12 2002-11-12 Pozen Inc. Treatment of migraine headache
US6310099B1 (en) * 1997-08-28 2001-10-30 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
US6054455A (en) * 1998-05-18 2000-04-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
US6384034B2 (en) * 1998-11-02 2002-05-07 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
WO2006122123A3 (en) * 2005-05-09 2007-06-07 Bruce H Levin Methods of alleviating disorders and their associated pain
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain

Also Published As

Publication number Publication date
ES2234324T3 (en) 2005-06-16
DE69922688T2 (en) 2005-12-01
AU1709800A (en) 2000-05-22
EP1126841A4 (en) 2002-06-12
EP1126841A1 (en) 2001-08-29
US20060194855A1 (en) 2006-08-31
ATE284691T1 (en) 2005-01-15
EP1126841B1 (en) 2004-12-15
US6384034B2 (en) 2002-05-07
AU759307B2 (en) 2003-04-10
DE69922688D1 (en) 2005-01-20
JP2002528498A (en) 2002-09-03
CA2348979A1 (en) 2000-05-11
WO2000025779A1 (en) 2000-05-11
US20020016348A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
US6384034B2 (en) Method of treating migraines and pharmaceutical compositions
WO1999026659A1 (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
US20040186155A1 (en) Combination therapy for the treatment or prevention of migraine
Mazaleuskaya et al. Druggable prostanoid pathway
ES2211867T5 (en) USE OF AN ANGIOTENSIN ANTAGONIST (AT1) TO REDUCE POST-INFARITY MORBIDITY AND MORTALITY.
EP2832357A1 (en) Selective AT2 receptor agonists for use in treatment of cachexia
US20020045605A1 (en) Method of treating colonic adenomas
EP1296665B1 (en) Analgesic and anti-inflammatory compositions containing celecoxib and ibuprofen
JP2000086629A (en) Net nitrogen oxide-releasing compound
JP2003512464A (en) New indole compounds
US8680081B2 (en) Prophylactic treatment of migraine
WO2003094924A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
AU2001268377A1 (en) Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
AU2002303577B2 (en) Method and compositions for treating migraines
CA2432504A1 (en) Methods and compositions for treating periodontal disease
AU2002303577A1 (en) Method and compositions for treating migraines
WO2022141328A1 (en) Use of thioimidazolidinone drug in treating covid-19-related diseases
WO1988009675A1 (en) Inhibition of arachidonic acid metabolism
EP0971714B1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
JP2004538292A (en) Drugs that inhibit the sodium-calcium exchange system
US20050215611A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
US20050059741A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
WO2008032814A1 (en) Aspirin-containing pharmaceutical agent

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION